LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.<\/p>\n
Libtayo (cemiplimab-rwlc injection) for intravenous use Initial U.S. Approval: 2018
\nTo access cemiplimab-rwlc injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN’s Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj)<\/p>\n","protected":false},"excerpt":{"rendered":"
Libtayo (cemiplimab) is a medication used for the treatment of advanced cutaneous squamous cell carcinoma (CSCC), advanced basal cell carcinoma (BCC) and advanced non-small cell lung cancer (NSCLC).<\/p>\n
Disease Indications-Lung Cancer, Skin Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cCemiplimab-rwlc Injection\u201d based on the information you provide.<\/strong><\/p>\n
\nManufacturer-Sanofi
\nUsage-Intravenous
\nMedicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n